最新以色列实战研究,Pfizer/BioNTech对南非和英国病毒有效性低。笑中国疫苗?Pfizer/BioNTech也在实验打第三针

billwanhua

本站元老
注册
2005-07-07
消息
15,318
荣誉分数
4,775
声望点数
373

Simultaneous measurements of the frequency of infection in carefully matched unvaccinated control populations allowed the scientists to calculate that the vaccine was eight times more protective against the wild type than the B1.351 variant. Similar studies showed that the vaccine is about 2.5 times more effective against the wild type than it is against the B 1.1.7 (UK) variant. The authors caution that although the direction of the protective effect against the three types of virus is clear, the actual magnitude of the difference is only approximate due to the limited number of breakthrough cases.
对南非病毒抵抗力低8倍,对英国病毒抵抗力低2.5倍。
In seeking to explain their observations the authors write, "From a biological point of view, the breakthrough cases observed in this study might either be due to immune evasion of both strains, or the ability of B.1.17 to create higher viral loads"

In commenting on their findings Adi Stern of Tel Aviv University was quoted as saying “We found a disproportionately higher rate of the South African variant among people vaccinated with a second dose, compared to the unvaccinated group. This means that the South African variant is able, to some extent, to break through the vaccine’s protection.”


They have been testing a third dose of their shot as a booster, and have said they could modify the shot to specifically address new variants if needed.
笑中国疫苗?Pfizer/BioNTech也在实验打第三针。
They also said the research was not intended to deduce overall vaccine effectiveness against any variant, since it only looked at people who had already tested positive for COVID-19, not at overall infection rates.以色列玩数字游戏?不公布有效性数字(即使不准确)是不是因为太低?

Pfizer declined to comment on the Israeli study.
看来对南非变异效果不大。
 
最后编辑:
麻烦大了
 

Simultaneous measurements of the frequency of infection in carefully matched unvaccinated control populations allowed the scientists to calculate that the vaccine was eight times more protective against the wild type than the B1.351 variant. Similar studies showed that the vaccine is about 2.5 times more effective against the wild type than it is against the B 1.1.7 (UK) variant. The authors caution that although the direction of the protective effect against the three types of virus is clear, the actual magnitude of the difference is only approximate due to the limited number of breakthrough cases.
对南非病毒抵抗力低8倍,对英国病毒抵抗力低2.5倍。
In seeking to explain their observations the authors write, "From a biological point of view, the breakthrough cases observed in this study might either be due to immune evasion of both strains, or the ability of B.1.17 to create higher viral loads"

In commenting on their findings Adi Stern of Tel Aviv University was quoted as saying “We found a disproportionately higher rate of the South African variant among people vaccinated with a second dose, compared to the unvaccinated group. This means that the South African variant is able, to some extent, to break through the vaccine’s protection.”


They have been testing a third dose of their shot as a booster, and have said they could modify the shot to specifically address new variants if needed.
笑中国疫苗?Pfizer/BioNTech也在实验打第三针。
They also said the research was not intended to deduce overall vaccine effectiveness against any variant, since it only looked at people who had already tested positive for COVID-19, not at overall infection rates.以色列玩数字游戏?不公布有效性数字(即使不准确)是不是因为太低?

Pfizer declined to comment on the Israeli study.
看来对南非变异效果不大。
晴空万里,裤衩一声,太可怕了。
 
晴空万里,裤衩一声,太可怕了。
咱们只打疫苗不行,还是要多管齐下,当务之急是不能让印度巴西等变种多的地区的人不停飞过来。
 
咱们只打疫苗不行,还是要多管齐下,当务之急是不能让印度巴西等变种多的地区的人不停飞过来。


现在已经来不及了。
加拿大国内已经有大量变异病毒。
 
咱们只打疫苗不行,还是要多管齐下,当务之急是不能让印度巴西等变种多的地区的人不停飞过来。
不停飞,就自求平安吧。
 
腺病毒疫苗集体杯具了。注射两针后,产生的抗体对付新冠蛋白的远低于对付载体病毒本身的。
第三针下去后,直接被机体消灭,打也白打,而且以后用该腺病毒做载体的其他疫苗也都大概率失效。这辈子算完了。
只有不断更换载体病毒,到哪里去找这么多种类不同的、又对人体又“无害”的腺病毒?
 
听专业人士说,mRNA疫苗对变种的增强版在研发中,因有了先前的基础,新版的研发和批准都会较快。
 
美国mrna已经在work on 新疫苗了。

中国灭活。哈哈能不打,就别打,给老向他们留着。

任何一个时刻,科学总是比没科学的强。继续笑。
 
腺病毒载体搭载个胰岛素基因,癌症相关反基因等我信,那是一锤子买卖;做流行病疫苗载体,我不信。
 
听专业人士说,mRNA疫苗对变种的增强版在研发中,因有了先前的基础,新版的研发和批准都会较快。
这种针对定点刺突防护的,只能像感冒疫苗一样每年不停打了。赶紧买疫苗公司股票
 
不停飞,就自求平安吧。
如果看以色列的研究报告的口气,虽然没有说有效性数字,但是庆幸以色列南非变种很少,说明以色列科学家言下之意就是没有什么保护能力。咱们也不能放变种病毒过来。
 
老向他们已经叛变了。改口说什么三种疫苗轮着打。。。。。。。。
 
腺病毒疫苗集体杯具了。注射两针后,产生的抗体对付新冠蛋白的远低于对付载体病毒本身的。
第三针下去后,直接被机体消灭,打也白打,而且以后用该腺病毒做载体的其他疫苗也都大概率失效。这辈子算完了。
只有不断更换载体病毒,到哪里去找这么多种类不同的、又对人体又“无害”的腺病毒?



阿斯利康不是有效么。
血栓是另外一回事。
 
后退
顶部